Pharmaceutical Technology

MAY 1, 2023

Under the deal terms, Shunxi will have licence to develop, manufacture, and commercialise CTH-004 to treat several solid tumours including ovarian cancer in Greater China, including Hong Kong, Taiwan, Mainland China, and Macao. Cartherics will retain all the development and commercialisation rights for the therapy outside Greater China.

Manufacturing 52

Manufacturing Patients Leads Pharmaceutical 52

Pharmaceutical Technology

JULY 14, 2022

Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). “The According to Kahn, this results in a need for improved and optimised commercialisation solutions across the industry.

Medicine 59

Medicine Marketing Specialization Pharma 59

Pharmaceutical Technology

NOVEMBER 9, 2022

CSL Behring has a commercialisation and license agreement to develop EtranaDez. million price tag. The post Can gene therapies for haemophilia defend their high price tags? A fair price for CSL Behring’s haemophilia B treatment etranacogene dezaparvovec would be between $2.93–2.96 million ($1.8 million at the time).

Safety 111

Safety Pharmaceutical Patients Medicine 111